Want to see AKTS full AI Analyst Report?

Aktis Oncology, Inc. (AKTS) Price & Analysis

40 Followers

AKTS Stock Chart & Stats

$26.92

Market closed

$26.92

Day’s Range― - ―

52-Week Range$14.72 - $34.19

Previous CloseN/A

VolumeN/A

Average Volume (3M)267.92K

Market Cap

$1.34B

Enterprise Value$1.28K

Total Cash (Recent Filing)$517.32M

Total Debt (Recent Filing)$11.24M

Price to Earnings (P/E)―

Beta2.20

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding53,746,670

10 Day Avg. Volume236,051

30 Day Avg. Volume267,915

Financial Highlights & Ratios

PEG Ratio3.39

Price to Book (P/B)-8.05

Price to Sales (P/S)181.08

P/FCF Ratio-15.96

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$36.50

Price Target Upside35.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ExpansionRevenue increased about 596% in 2025 versus 2024, showing that the company is expanding from its small starting base. If this ramp persists, greater commercial scale could improve operating leverage and provide a broader foundation for future funding and development.

Strong Gross MarginThe reported strong gross margin indicates that revenue carries substantial contribution after direct costs, an important foundation for eventual operating leverage. Although current expenses overwhelm it, preserving this margin as sales scale could support better economics over the next several quarters.

Modest Absolute DebtTotal debt was about $11.5M in 2025, described as modest in absolute dollars. This limits the direct burden of contractual borrowing relative to a more heavily leveraged structure, leaving debt service less central to the funding challenge even though equity remains deeply negative.

Bears Say

Severe Net LossesThe approximately $63.7M 2025 net loss on only $6.5M of revenue shows that operating costs remain far above the company’s current revenue base. Persistent losses weaken internal funding capacity and indicate that substantial execution is required before profitability can become durable.

Heavy Cash BurnThe reversal from positive 2024 cash flow to approximately $64.1M of operating cash burn and $73.7M of negative free cash flow materially increases funding needs. Continued burn can constrain investment choices and heighten reliance on external capital over the coming quarters.

Negative Deteriorating EquityEquity deteriorated substantially further into negative territory during 2025, reaching approximately -$146.1M. This weakens the balance-sheet cushion, increases financing and potential dilution risk, and leaves the company less resilient if losses and cash needs remain elevated.

Aktis Oncology, Inc. News

Oppenheimer bullish on Aktis Oncology, initiates with an Outperform

As previously reported, Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target...

2d ago

AKTS

Aktis Oncology initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target Published first on...

2d ago

AKTS

Wedbush starts Aktis Oncology at Outperform on radiopharma potential

Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target...

23d ago

AKTS

Aktis Oncology initiated with an Outperform at Wedbush

Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target...

23d ago

AKTS

BMO starts Aktis at Outperform, says opportunities not captured in valuation

BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price...

24d ago

AKTS

Aktis Oncology initiated with an Outperform at BMO Capital

BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price...

24d ago

AKTS

Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M

“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to...

26d ago

AKTS

Fifteen new option listings on July 15th

New option listings for July 15th include Aktis Oncology Inc (AKTS), Avidia Bancorp Inc (AVBC), Infoblox Inc (BLOX),...

2M ago

AKTS

AVBC

Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy Benchmark

William Blair analyst Alexandra Ramsey has maintained their bullish stance on AKTS stock, giving a Buy rating today....

2M ago

AKTS

Aktis Oncology price target raised to $33 from $30 at JPMorgan

JPMorgan raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps an Overweight...

2M ago

AKTS

Aktis Oncology initiated with a Strong Buy at Raymond James

Raymond James analyst Christopher Raymond initiated coverage of Aktis Oncology (AKTS) with a Strong Buy rating and $40...

3M ago

AKTS

Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC

William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating yesterday....

3M ago

AKTS

Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Aktis Oncology, Inc.. The...

4M ago

AKTS

Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity

William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating on...

4M ago

AKTS

AKTS FAQ

What was Aktis Oncology, Inc.’s price range in the past 12 months?

Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.

What is Aktis Oncology, Inc.’s market cap?

Aktis Oncology, Inc.’s market cap is $1.34B.

When is Aktis Oncology, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Aktis Oncology, Inc.’s earnings last quarter?

Currently, no data Available

Is Aktis Oncology, Inc. overvalued?

According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aktis Oncology, Inc. pay dividends?

Aktis Oncology, Inc. does not currently pay dividends.

What is Aktis Oncology, Inc.’s EPS estimate?

Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aktis Oncology, Inc. have?

Aktis Oncology, Inc. has 53,746,670 shares outstanding.

What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aktis Oncology, Inc.?

Currently, no hedge funds are holding shares in AKTS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aktis Oncology, Inc. Stock Smart Score

Neutral

Company Description

Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Aktis Oncology, Inc. (AKTS) Earnings & Revenues

Historic Earnings Reports

AKTS Stock 12 Month Forecast

Average Price Target

$36.50

▲(35.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","41":"$41","22.25":"$22.3","28.5":"$28.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,22.25,28.5,34.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.99,27.067692307692305,28.145384615384614,29.22307692307692,30.30076923076923,31.378461538461536,32.456153846153846,33.533846153846156,34.61153846153846,35.68923076923077,36.76692307692308,37.84461538461538,38.92230769230769,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.99,26.798461538461538,27.606923076923074,28.415384615384614,29.223846153846154,30.03230769230769,30.84076923076923,31.64923076923077,32.457692307692305,33.26615384615385,34.074615384615385,34.88307692307692,35.69153846153846,{"y":36.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.99,26.529230769230768,27.068461538461538,27.607692307692307,28.146923076923077,28.686153846153847,29.225384615384616,29.764615384615382,30.303846153846152,30.84307692307692,31.38230769230769,31.92153846153846,32.46076923076923,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.4,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >